Audubon-based Globus Medical has announced its acquisition of California life sciences company Nevro Corp. for $250 million ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Globus Medical reports Q4 2024 sales of $657 million ... Inc. was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

While Nevro recorded income of around $408 million, Globus Medical's sales at $2.52 billion showed a 60.6% annual rise year over year. Globus anticipates $2.80 billion to $2.90 billion in sales ...

The company currently has its sales operations distributed across 51 counties worldwide. With the complementary strengths of Globus Medical engineering and NuVasive relations, education and ...

Globus Medical reported preliminary sales projections for 2024 of $2.52 billion, while Nevro expects revenues between $408 million to $409 million. Globus Medical's acquisition of Nevro will ...

On a stand-alone basis, Globus Medical (GMED) reaffirms guidance for 2025 net sales of $2.66B to $2.69B and fully diluted non-GAAP earnings per share range between $3.40 to $3.50; Revenue ...

Globus said it anticipates in annual net sales this year to total between $2.8 billion and $2.9 billion. Globus Medical’s financial adviser for the deal is Morgan Stanley & Co. Wyrick Robbins ...

Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over prior year on an as-reported basis; and On January 13, 2025, Nevro announced preliminary 2024 ...

Globus Medical (GMED) also reaffirmed its guidance for 2025 net sales of $2.66B to $2.69B and non-GAAP EPS of $3.40 to $3.50. Following the merger, Globus Medical (GMED) expects 2025 net sales of ...